

SL-33

doi: 10.14232/tnpr.2019.sl33

***In vitro* antitumor activity of protoflavone-based hybrid compounds on human gynecological cancer cell lines**

Ahmed Latif^{1,2,*}, Máté Vágvölgyi¹, Gábor Girst¹, Tamás Jenei³, István Zupkó², Antal Csámpai³ and Attila Hunyadi¹

¹ Institute of Pharmacognosy, University of Szeged, Szeged, Hungary

² Department of Pharmacodynamics and Biopharmacy, University of Szeged, Szeged, Hungary

³ Institute of Chemistry, Eötvös Loránd University, Budapest, Hungary

*E-mail: alhussainy53@yahoo.com

Protoflavones are rare and unusual flavonoid derivatives having a non-aromatic B-ring; in nature, they can most typically be found in certain genera of fern species. Protoflavones are promising, natural anticancer agents, and their *in vitro* and *in vivo* activity inspired the synthesis of many semi- and total synthetic analogs [1]. In the current study, our aim was to evaluate the antitumor potential of a set of new hybrid compounds, each containing a protoflavone and a chalcone or ferrocene fragment.

Four new compounds were prepared and studied for their *in vitro* antitumor activity against four gynecological human cancer cell lines including HeLa and SiHa (cervical), and MCF-7 and MDA-MB-231 (breast) cancer cells, with cisplatin as a positive control. When testing by MTT assay, the compounds showed strong antiproliferative activities with IC₅₀ values in the low-medium nanomolar range. To quantitatively evaluate pharmacological benefit gained by the coupling, bioactivity of each compound was further analyzed in a virtual combination study, i.e. considering it as an interaction of a 1:1 ratio mixture of the corresponding protoflavone and chalcone building block. The most potent compound demonstrated an IC₅₀ value of 153 nM against SiHa cells, representing a combination index value of 0.10 (i.e. very strong synergism) for the two separate fragments. This compound was found to induce apoptosis in MDA-MB-231 and SiHa cells through the significant increase in the hypodiploid (sub G1) population as evidenced by cell cycle analysis and induced the activation of caspase-3.

Our study highlights the pharmacological potential of protoflavone-based hybrid compounds and demonstrates that these hybrids are much more than a simple addition of their chemical elements.

Acknowledgements

This work was supported by the National Research, Development and Innovation Office, Hungary (NKFIH; K119770, K109293, and K129037). A.H. acknowledges the János Bolyai fellowship of the Hungarian Academy of Sciences, the UNKP-18-4 New National Excellence Program of the Ministry of Human Capacities and the Kálmán Szász Prize.

Reference

[1] Hunyadi A et al. *Phytochem Rev.* 2014; 13:69-77.